management of bladder cancer patients during COVID-19 pandemic, delaying bladder cancer treatment during COVID-19 pandemic, access to emergency room during COVID-19 pandemic, analysis of first COVID-19 outbreak in Italy.
Zach Klaassen engages with Colin Pritchard in a detailed discussion about genomic testing in prostate cancer. They emphasize the importance of genomic testing, particularly in…
Alicia Morgans interviews Neeraj Agarwal about the CONTACT-02 trial, a phase III study that explores the combination of cabozantinib and atezolizumab in patients with metastatic…
Zach Klaassen and Aaron Berger explore the evolving landscape of non-metastatic castration-resistant prostate cancer (CRPC). Dr. Berger highlights the decreasing frequency of non-metastatic CRPC in…
Daniel George and Stephen Freedland delve into the EMBARK study, a trial on Enzalutamide for high-risk non-metastatic biochemical recurrence of prostate cancer. They explore the…
Shilpa Gupta discusses the challenges and progress of the MAIN-CAV study examining the combination of treatments for urothelial cancer in the U.S., impacted by a…
Emily Clennon discusses her research on the transfer of pediatric torsion patients to pediatric hospitals. Published with Dr. Duty and Dr. Seideman, the study addresses…
COVID-19 Public Health Emergency, radical cystectomy and bladder-sparing therapy for recurrent high-risk non-muscle-invasive bladder cancer (NMIBC), CISTO network, intravesical bacillus Calmette-Guerin (BCG), TURBT and radical…
prostate cancer, metastatic hormone sensitive prostate cancer (mHSPC), Metastatic Hormone-sensitive Prostate Cancer Treatment, Docetaxel, Novel Hormonal Therapy (NHT), enzalutamide, apalutamide, abiraterone, androgen deprivation therapy (ADT).
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Bone Health Management for Advanced Prostate Cancer – Fred Saad Part…
Neal Shore discusses the ARASENS trial’s post hoc analysis, emphasizing the benefits of triplet therapy in advanced hormone-sensitive prostate cancer. This study adds to the…
